文献速递膀胱癌与上尿路尿路上皮癌

程序性死亡受体1或程序性死亡配体1阻断治疗铂类耐药转移性尿路上皮癌:系统评价与Meta分析

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2019-06-11

该系统评价与Meta分析纳入6项临床试验,重建1315例接受PD-1/PD-L1抑制剂和736例接受化疗的铂类耐药转移性尿路上皮癌患者的生存数据。随访12和18个月时PD-1/PD-L1阻断的受限平均生存时间分别为7.8个月和10个月。PD-1与PD-L1阻断的生存结局相当。

要点

  • PD-1/PD-L1阻断随访12和18个月的受限平均生存时间分别为7.8个月和10个月。
  • 两项随机试验的网络Meta分析显示PD-1与PD-L1阻断18个月内受限平均生存时间无显著差异。
  • 全部六项试验重建数据显示PD-1与PD-L1阻断的生存结局相当。

核心结论

  • 受限平均生存时间估计值可作为基准用于解读生存结局并指导未来PD-1/PD-L1抑制剂试验设计。
  • PD-1与PD-L1阻断在转移性尿路上皮癌患者中产生相当的生存结局。

研究设计与样本

  • 系统评价与Meta分析,检索1、2、3期临床试验,评估PD-1或PD-L1抑制用于铂类耐药转移性尿路上皮癌患者。
  • 文献回顾、研究选择、数据提取和偏倚风险评估由两名评价者完成。
  • 使用算法从已发表的Kaplan-Meier曲线推导个体时间-事件数据以重建生存数据。
  • 从836篇参考文献中纳入6项临床试验,重建1315例接受PD-1/PD-L1抑制剂和736例接受化疗患者的生存数据。

主要发现

  • PD-1/PD-L1阻断随访至12和18个月的受限平均生存时间分别为7.8个月(95%CI 7.6,8.1)和10个月(95%CI 9.7,10.5)。
  • 两项随机试验的网络Meta分析显示PD-1与PD-L1阻断随访至18个月的受限平均生存时间无显著差异(1.0个月;95%CI -0.5,2.3个月)。
  • 全部六项试验重建数据显示,PD-1与PD-L1阻断随访至12个月的受限平均生存时间分别为7.8个月(95%CI 7.7,8.2)与7.8个月(95%CI 7.5,8.2)。
  • 全部六项试验重建数据显示,PD-1与PD-L1阻断随访至18个月的受限平均生存时间分别为10.1个月(95%CI 9.6,10.7)与10个月(95%CI 9.5,10.6)。

关键数值与推荐

  • PD-1/PD-L1阻断随访至12个月的受限平均生存时间为7.8个月(95%CI 7.6,8.1)。
  • PD-1/PD-L1阻断随访至18个月的受限平均生存时间为10个月(95%CI 9.7,10.5)。
  • PD-1与PD-L1阻断随访至18个月的受限平均生存时间差异为1.0个月(95%CI -0.5,2.3个月),无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Several anti-programmed death-1 (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1) antibodies have been approved by regulatory authorities for treatment of platinum-resistant metastatic urothelial cancer (mUC). The impact of these therapies on survival, and comparability of PD-1 versus PD-L1 blockade are unknown. OBJECTIVE: To determine the restricted mean survival time (RMST) of patients with platinum-resistant mUC treated with PD-1/PD-L1 inhibitors and to compare RMSTs in patients treated with PD-1 versus PD-L1 inhibitors. EVIDENCE ACQUISITION: We searched for phase 1, 2, and 3 clinical trials that assessed PD-1 or PD-L1 inhibition for patients with platinum-resistant mUC. Literature review and study selection, data abstraction, and risk of bias assessment were performed by two reviewers. Survival data were reconstructed using an algorithm that derives individual time-to-event data from published Kaplan-Meier curves. The RMST with 95% confidence interval (CIs) was calculated. EVIDENCE SYNTHESIS: From 836 references, six clinical trials were included. Survival data were reconstructed for 1315 and 736 patients treated with PD-1/PD-L1 inhibitors and chemotherapy, respectively. The RMSTs with PD-1/PD-L1 blockade up to 12 and 18mo of follow-up were 7.8mo (95% CI 7.6, 8.1) and 10mo (95% CI 9.7, 10.5), respectively. A network meta-analysis of two randomized trials revealed no significant difference in the RMST up to 18mo with PD-1 versus PD-L1 blockade (1.0mo; 95% CI -0.5, 2.3mo). Using reconstructed survival data from all six trials, the RMSTs with PD-1 versus PD-L1 blockade up to 12 and 18mo follow-up were 7.8mo (95% CI 7.7, 8.2) versus 7.8mo (95% CI 7.5, 8.2) and 10.1mo (95% CI 9.6, 10.7) versus 10mo (95% CI 9.5, 10.6), respectively. CONCLUSIONS: Our RMST estimates may be used as benchmarks to contextualize survival outcomes and inform future trial design with PD-1/PD-L1 inhibitors. PD-1 versus PD-L1 blockade in patients with mUC yields comparable survival outcomes. PATIENT SUMMARY: In this study, we found that outcomes for patients with metastatic bladder cancer treated with programmed death-1 and programmed death ligand-1 inhibitors, who received prior platinum-based chemotherapy, were similar.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Niglio SA, Jia R, Ji J, et al. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2019. PMID: 31200951. doi:10.1016/j.eururo.2019.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。